The heterobivalent (SSTR2/albumin) radioligand [Cu]Cu-NODAGA-cLAB4-TATE enables efficient somatostatin receptor radionuclide theranostics.

Somatostatin type 2 receptor (SSTR2) radionuclide therapy using β particle-emitting radioligands has entered clinical practice for the treatment of neuroendocrine neoplasms (NENs). Despite the initial success of [Lu]Lu‑DOTA-TATE, theranostic SSTR2 radioligands require improved pharmacokinetics and enhanced compatibility with alternative radionuclides. Consequently, this study evaluates the pharmacokinetic effects of the albumin-binding domain cLAB4 on theranostic performance of copper‑67-labeled NODAGA-TATE variants in an SSTR2-positive mouse pheochromocytoma (MPC) model.

Cyclohexanediamine Triazole (CHDT) Functionalization Enables Labeling of Target Molecules with AlF/Ga/In.

The AlF-labeling approach offers a one-step access to radiofluorinated biomolecules by mimicking the labeling process for radiometals. Although these labeling conditions are considered to be mild compared to classic radiofluorinations, improvements of the chelating units have led to the discovery of , which allows AlF-labeling already at ambient temperature. While the suitability of for functionalization and radiofluorination of proteins is well established, its use for small molecules or peptides is less explored.

Pathogenic RW Variant of the Copper Chaperone for Sod1 (Ccs) Functions as an Anti-chaperone.

The copper chaperone for Sod1 (Ccs) is a metallochaperone that plays a multifaceted role in the maturation of Cu,Zn superoxide dismutase (Sod1). The Ccs mutation RW was identified in an infant with fatal neurological abnormalities. Based on a comprehensive structural and functional analysis, we developed the first data-driven model for RW-related pathogenic phenotypes.

Clustering Runners' Response to Different Midsole Stack Heights: A Field Study.

Advanced footwear technology featuring stack heights higher than 30 mm has been proven to improve running economy in elite and recreational runners. While it is understood that the physiological benefit is highly individual, the individual biomechanical response to different stack heights remains unclear. Thirty-one runners performed running trials with three different shoe conditions of 25 mm, 35 mm, and 45 mm stack height on an outdoor running course wearing a STRYD sensor.